Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Leukemia, Myeloid, Acute 228Leukemia, Lymphocytic, Chronic, B-Cell 211Leukemia 201Myelodysplastic Syndromes 184Precursor Cell Lymphoblastic Leukemia-Lymphoma 172Lymphoma 147Lymphoma, Non-Hodgkin 141Multiple Myeloma 130Hodgkin Disease 121Lymphoma, Follicular 110Lymphoma, Mantle-Cell 107Lymphoma, Large B-Cell, Diffuse 95Lymphoma, B-Cell, Marginal Zone 88Myeloproliferative Disorders 86Congenital Abnormalities 84Burkitt Lymphoma 84Leukemia, Myelomonocytic, Chronic 77Leukemia, Myelogenous, Chronic, BCR-ABL Positive 75Leukemia, Myeloid, Chronic-Phase 74Leukemia, Myeloid, Accelerated Phase 72Recurrence 62Melanoma 62Lymphoma, Large-Cell, Immunoblastic 60Anemia, Refractory, with Excess of Blasts 60Primary Myelofibrosis 55Neoplasms, Plasma Cell 55Waldenstrom Macroglobulinemia 54Blast Crisis 54Hematologic Neoplasms 44Lymphoma, T-Cell, Cutaneous 42

Interventions

fludarabine phosphate 1fludarabine 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Mesothelin-positive Advanced Refractory Solid Tumors × fludarabine phosphate × Clear all
NCT05531708 2023-03-01

Exploratory Study of Novel MSLN CAR-T Cell Therapy in Patients With MSLN-positive Advanced Refractory Solid Tumors

Shanghai Pudong Hospital

Phase 1 Withdrawn
Other solid neoplasm

Mesothelin-positive Advanced Refractory Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡